MCDERMID v. INOVIO PHARMACEUTICALS, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedJanuary 18, 2023
Docket2:20-cv-01402
StatusUnknown

This text of MCDERMID v. INOVIO PHARMACEUTICALS, INC. (MCDERMID v. INOVIO PHARMACEUTICALS, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
MCDERMID v. INOVIO PHARMACEUTICALS, INC., (E.D. Pa. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA PATRICK MCDERMID, individually and on behalf of all others similarly situated, Plaintiff, CIVIL ACTION NO. 20-01402 v. INOVIO PHARMACEUTICALS, INC., et al, Defendants.

PAPPERT, J. January 18, 2023 MEMORANDUM

The parties have agreed to settle this class action after almost three years of litigation. The Court issued an Order on August 31, 2022, preliminarily approving the settlement. (ECF 150.) Plaintiffs now move for final approval of the Settlement Agreement, Plan of Allocation, award for attorneys’ fees, expenses, and awards to the lead and representative Plaintiffs. (ECF 156.) After reviewing all relevant submissions and holding a hearing (ECF 160), the Court grants the Motion. I Patrick McDermid, individually and on behalf of others similarly situated, sued Inovio, CEO J. Joseph Kim, CFO Peter D. Kies, and Vice President of Biological Manufacturing and Clinical Supply Management Robert J. Juba, Jr. alleging violations of sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 and SEC Rule 10b-5. Plaintiffs claim that during the class period, Defendants made several false or misleading statements regarding Inovio’s progress on a COVID-19 vaccine that artificially inflated Inovio’s stock price. For example, on February 14, 2020, Kim announced on television that “within three hours of accessing [COVID-19’s genetic sequence] . . . we were able to construct our vaccine INO-4800.” (Second Am. Compl. ¶ 97, ECF 129.) His announcement caused Inovio’s stock price to increase 7.5 percent. (Id. ¶ 98.) On March 2, 2020, Kim met with then-President Trump, and while discussing the COVID-19 pandemic, stated that Inovio had “fully construct[ed] [its

COVID-19] vaccine within three hours.” (Id. ¶ 99.) Inovio’s stock rose 69.7 percent by the end of the next day. (Id. ¶ 100.) After Kim’s statements, Citron Research—a well-known securities trading and research firm—denounced on Twitter Inovio’s “ludicrous and dangerous” claim that it designed a vaccine in 3 hours. (Id. ¶ 115). Inovio later corrected Kim’s statements, conceding it had not constructed a vaccine in three hours, as Kim had claimed; rather, it had designed a vaccine in three hours. (Id. ¶ 101.) Over the following months, further misstatements were revealed, such as Inovio’s assertion that it could manufacture hundreds of millions of doses of its vaccine. (Id. ¶¶ 103–107.) Within two days, Inovio’s stock tumbled from $18.72 per share to just $5.70 per share. (Id. ¶¶ 115–116.) Over

the following months, further company statements—such as Inovio’s assertion that it could manufacture hundreds of millions of doses of its vaccine—were revealed as misleading. (Id. ¶ 74, 103–107.) The litigation “was hotly disputed on both sides,” and both parties “were fully prepared to take this case forward” to trial. (Hr’g Tr. 10:4–6, ECF 161.) McDermid filed his initial Complaint on March 12, 2020 (ECF 1), and the Court appointed Manuel Williams as lead Plaintiff and Robbins Geller Rudman & Dowd LLP as lead counsel in June of 2020. See (ECF 54.) Plaintiffs filed their Consolidated Class Action Complaint (ECF 60) in August of 2020, and a First Amended Complaint in September of 2020 (ECF 68). On February 16, 2021, the Court granted in part and denied in part Defendants’ Motion to Dismiss (ECF 72, 86). Plaintiffs filed and fully briefed a Motion to Certify the Class (ECF 99), to which the Defendants filed a thorough Response (ECF 107). Plaintiffs filed a Second Amended Complaint in February of 2022 (ECF 129), to

which Defendants filed another Motion to Dismiss (ECF 133). Throughout this time, the parties engaged in extensive discovery consisting of over half a million pages of documents. Plaintiffs deposed nineteen fact witnesses, and experts for both sides prepared reports and were deposed. (Mem. L. Supp. Mot. Final Approval 9, ECF 156- 1.) The parties also participated in two mediations with a mediator with extensive experience in complex class action cases. (Decl. of Tor Gronborg Supp. Mot. Final Approval ¶ 4, ECF 156-2.) The parties eventually reached agreement, and the Court preliminarily approved their settlement (ECF 150). On December 15, 2022, the Court held a hearing on the Final Settlement Agreement (ECF 160). Under the Settlement Agreement, Inovio agrees to pay an award of at least

$44 million. Of that total, $30 million will be paid in cash, with the remainder paid in either seven million shares of Inovio common stock or $14 million worth of stock, whichever is greater. (Mem. L. Supp. Mot. Final Approval 1, ECF 156-1.) Each individual class member’s recovery will depend on when they purchased their Inovio stock, how much they paid for their stock, and how many shares the individual purchased. (Decl. of Tor Gronborg Supp. Mot. Final Approval ¶ 87, ECF 156-2.) II Pursuant to Federal Rule of Civil Procedure 23(e), class actions may only be settled with court approval and only after a hearing that finds the settlement is “fair, reasonable, and adequate.” Fed. R. Civ. P. 23(e)(2). The Court must: (1) determine if the requirements for class certification under Rule 23(a) and (b) are satisfied; (2) assess whether notice to the proposed class was adequate; and (3) evaluate if the proposed settlement is fair under Rule 23(e). See In re Nat’l Football League Players Concussion

Inj. Litig., 775 F.3d 570, 581 (3d Cir. 2014). III

The settlement class must meet Rule 23(a)’s requirements: numerosity, commonality, typicality, and adequacy of representation. Fed. R. Civ. P. 23(a). These requirements ensure that the named plaintiffs appropriately represent the class and “effectively limit[s] the class claims to those fairly encompassed by the named plaintiff’s claims.” Wal-Mart Stores, Inc. v. Dukes, 564 U.S. 338, 349 (2011) (citations and quotations omitted). Because the numerosity requirement is generally met if the potential number of plaintiffs exceeds forty, Stewart v. Abraham, 275 F.3d 220, 226–27 (3d Cir. 2001), the “thousands” of class members who purchased Inovio stock during the class period are sufficiently numerous as to make joinder impractical under Rule 23(a). See (Mem. L. Supp. Mot. Class Certification 3, ECF 100); In re CIGNA Corp. Sec. Litig., No. 02-cv- 8088, 2006 WL 2433779, at *2 (E.D. Pa. Aug. 18, 2006) (“[C]ourts have recognized a presumption that the ‘numerosity requirement is satisfied when a class action involves a nationally traded security.’”). The commonality bar “is not a high one.” Rodriguez v. Nat’l City Bank, 726 F.3d 372, 382 (3d Cir. 2013). A single common issue is enough to satisfy the commonality

requirement. See Baby Neal v. Casey, 43 F.3d 48, 56 (3d Cir. 1994). Typicality requires the Court to assess “whether the action can be efficiently maintained as a class and whether the named plaintiffs have incentives that align with those of absent class members so as to assure that the absentee’s interests will be fairly represented.” Id. at 57. Here, both the commonality and typicality requirements are met. The issues of law

and fact in this case are common to all class members.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Ehrheart v. Verizon Wireless
609 F.3d 590 (Third Circuit, 2010)
In Re Pet Food Products Liability Litigation
629 F.3d 333 (Third Circuit, 2010)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
Baby Neal v. Casey
43 F.3d 48 (Third Circuit, 1994)
United States v. Joseph P. Moses
148 F.3d 277 (Third Circuit, 1998)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Robert Stewart v. Lynne Abraham
275 F.3d 220 (Third Circuit, 2001)
In Re Baby Products Antitrust Litigation
708 F.3d 163 (Third Circuit, 2013)
John Rodriguez v. Natl City Bank
726 F.3d 372 (Third Circuit, 2013)
In Re Diet Drugs
582 F.3d 524 (Third Circuit, 2009)
Lachance v. Harrington
965 F. Supp. 630 (E.D. Pennsylvania, 1997)
In Re Corel Corp. Inc. Securities Litigation
293 F. Supp. 2d 484 (E.D. Pennsylvania, 2003)
In Re Computron Software, Inc., Securities Litigation
6 F. Supp. 2d 313 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
MCDERMID v. INOVIO PHARMACEUTICALS, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/mcdermid-v-inovio-pharmaceuticals-inc-paed-2023.